CT SB00313

Adds definition of "biological product" aligned with federal law (42 USC 262(i)) and establishes criteria for "interchangeable" biological products based on FDA determinations or therapeutic equivalence with A ratings.

Permits pharmacists to substitute prescribed biological products with interchangeable alternatives without patient or prescriber objection, mirroring existing generic drug substitution authority.

Requires prescribers to explicitly specify "brand medically necessary" or "no substitution" to prevent biological product substitution, with specific procedures for written, telephonic, and electronic prescriptions.

Mandates pharmacists notify prescribers and patients of biological product substitutions and provide cost savings information; requires labeling with the specific biological product name and manufacturer.

Requires pharmacists to electronically notify prescribers within five business days of which biological product was dispensed, accessible through electronic medical records, e-prescribing systems, or pharmacy records; effective October 1, 2016.